Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

University of Southern California

Status

Enrolling

Conditions

Stage IA Cervical Cancer AJCC v8

Stage II Differentiated Thyroid Gland Carcinoma AJCC v8

Stage IIIA Colorectal Cancer AJCC v8

Non-Hodgkin Lymphoma

Prognostic Stage IIIA Breast Cancer AJCC v8

Stage IIIC Colorectal Cancer AJCC v8

Stage III Thyroid Gland Medullary Carcinoma AJCC v8

Clinical Stage II Cutaneous Melanoma AJCC v8

Stage IB1 Cervical Cancer AJCC v8

Stage IIA Ovarian Cancer AJCC v8

Malignant Brain Neoplasm

Stage IIIA Cervical Cancer AJCC v8

Stage IIA Colorectal Cancer AJCC v8

Anatomic Stage II Breast Cancer AJCC v8

Clinical Stage IA Cutaneous Melanoma AJCC v8

Stage II Colorectal Cancer AJCC v8

Central Nervous System Neoplasm

Anatomic Stage IIIA Breast Cancer AJCC v8

Stage IIIB Uterine Corpus Cancer AJCC v8

Stage I Thyroid Gland Medullary Carcinoma AJCC v8

Stage IB2 Cervical Cancer AJCC v8

Stage I Uterine Corpus Cancer AJCC v8

Stage IIB Cervical Cancer AJCC v8

Prognostic Stage IB Breast Cancer AJCC v8

Stage II Thyroid Gland Medullary Carcinoma AJCC v8

Stage IIIC Ovarian Cancer AJCC v8

Stage IA2 Cervical Cancer AJCC v8

Anatomic Stage IIA Breast Cancer AJCC v8

Prognostic Stage III Breast Cancer AJCC v8

Clinical Stage III Cutaneous Melanoma AJCC v8

Stage IIIA2 Ovarian Cancer AJCC v8

Stage IIIB Ovarian Cancer AJCC v8

Stage III Ovarian Cancer AJCC v8

Stage IIA Cervical Cancer AJCC v8

Stage IA Uterine Corpus Cancer AJCC v8

Stage IB Cervical Cancer AJCC v8

Prognostic Stage II Breast Cancer AJCC v8

Anatomic Stage IA Breast Cancer AJCC v8

Stage IB Uterine Corpus Cancer AJCC v8

Clinical Stage IB Cutaneous Melanoma AJCC v8

Stage III Uterine Corpus Cancer AJCC v8

Prognostic Stage IIA Breast Cancer AJCC v8

Stage IC Ovarian Cancer AJCC v8

Stage IIC Colorectal Cancer AJCC v8

Stage III Differentiated Thyroid Gland Carcinoma AJCC v8

Anatomic Stage IIB Breast Cancer AJCC v8

Pathologic Stage IIID Cutaneous Melanoma AJCC v8

Clinical Stage IIC Cutaneous Melanoma AJCC v8

Prognostic Stage IA Breast Cancer AJCC v8

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8

Prognostic Stage I Breast Cancer AJCC v8

Stage IIIA Ovarian Cancer AJCC v8

Stage I Differentiated Thyroid Gland Carcinoma AJCC v8

Prognostic Stage IIB Breast Cancer AJCC v8

Stage IIIA1 Ovarian Cancer AJCC v8

Stage IIIC Uterine Corpus Cancer AJCC v8

Pathologic Stage IB Cutaneous Melanoma AJCC v8

Stage IIB Colorectal Cancer AJCC v8

Stage IIB Ovarian Cancer AJCC v8

Stage IIA1 Cervical Cancer AJCC v8

Pathologic Stage IIIC Cutaneous Melanoma AJCC v8

Pathologic Stage II Cutaneous Melanoma AJCC v8

Pathologic Stage I Cutaneous Melanoma AJCC v8

Stage IA Ovarian Cancer AJCC v8

Stage IIIC2 Uterine Corpus Cancer AJCC v8

Stage IA1 Cervical Cancer AJCC v8

Hodgkin Lymphoma

Malignant Bone Neoplasm

Prognostic Stage IIIC Breast Cancer AJCC v8

Stage IIIB Colorectal Cancer AJCC v8

Clinical Stage I Cutaneous Melanoma AJCC v8

Prognostic Stage IIIB Breast Cancer AJCC v8

Anatomic Stage IIIB Breast Cancer AJCC v8

Stage IIA2 Cervical Cancer AJCC v8

Pathologic Stage IIC Cutaneous Melanoma AJCC v8

Anatomic Stage IIIC Breast Cancer AJCC v8

Stage IIIA Uterine Corpus Cancer AJCC v8

Anatomic Stage IB Breast Cancer AJCC v8

Stage I Colorectal Cancer AJCC v8

Stage II Uterine Corpus Cancer AJCC v8

Clinical Stage IIB Cutaneous Melanoma AJCC v8

Stage I Cervical Cancer AJCC v8

Pathologic Stage IIA Cutaneous Melanoma AJCC v8

Stage IIIB Cervical Cancer AJCC v8

Stage II Ovarian Cancer AJCC v8

Stage II Cervical Cancer AJCC v8

Pathologic Stage IIIA Cutaneous Melanoma AJCC v8

Pathologic Stage III Cutaneous Melanoma AJCC v8

Clinical Stage IIA Cutaneous Melanoma AJCC v8

Stage IIIC1 Uterine Corpus Cancer AJCC v8

Stage III Cervical Cancer AJCC v8

Pathologic Stage IA Cutaneous Melanoma AJCC v8

Malignant Solid Neoplasm

Anatomic Stage I Breast Cancer AJCC v8

Stage I Ovarian Cancer AJCC v8

Stage IB Ovarian Cancer AJCC v8

Anatomic Stage III Breast Cancer AJCC v8

Malignant Testicular Neoplasm

Stage III Colorectal Cancer AJCC v8

Pathologic Stage IIB Cutaneous Melanoma AJCC v8

Treatments

Other: Quality-of-Life Assessment

Other: Survey Administration

Other: Medical Device Usage and Evaluation

Study type

Observational

Funder types

Other

NIH

Identifiers

NCT07259304

NCI-2021-05723 (Registry Identifier)

0S-20-10 (Other Identifier)

R37CA256867 (U.S. NIH Grant/Contract)

P30CA014089 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This study assesses how personal relationships (such as friendships, family relationships, or romantic partners) influence the physical activity (exercise) and well-being of young adult cancer survivors. Researchers also hope to learn how social relationships change after a cancer diagnosis, and how these changes might impact important health behaviors. The information provided may help researchers learn more about better ways to support young cancer patients in the future through interventions that help maintain good social relationships and health levels of physical activity.

Full description

PRIMARY OBJECTIVES:

I. Characterize the trajectories of social health in young adult (YA) cancer patients.

II. Investigate the longitudinal associations between social health and activity behaviors in YA cancer patients.

III. Explore the effects of sociodemographic and clinical characteristics on the relationship between social health, activity behaviors, and quality of life.

OUTLINE:

Patients complete surveys over 40 minutes and wear an actigraph GT3X-BT accelerometer continuously for 7 days at baseline, 3, 6, and 12 months.

Enrollment

250 estimated patients

Sex

All

Ages

18 to 39 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosed and/or treated with cancer between ages 18-39 at USC hospitals.
Cancer types prototypical for adolescents and young adults (AYAs) and cancer stages I-III; select patients with stage IV disease may be eligible, with approval by the principal investigator (PI) and in consultation with the treating clinician.
Must be within three months of a de novo cancer diagnosis at recruitment and on/indicated for curative therapy (any modality). Patients may continue on adjuvant therapy throughout duration of the study.
Patients must have anticipated survival of >1-year at time of diagnosis.

Exclusion criteria

Diagnosis of blood malignancies such as leukemias (these cancers have divergent treatment patterns of longer duration than other cancers and are more commonly pediatric cancers). Some early stage lymphomas with favorable prognoses may be eligible, with approval by the PI and in consultation with the treating clinician.
Primary language other than English or Spanish.
Inability to complete a survey and/or wear an accelerometer either per the patient or in consultation with the clinician's judgment.